metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE ...
Journal Information
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Share
Share
Download PDF
More article options
Vol. 28. Issue S1.
Abstracts of the 2022 Annual Meeting of the ALEH
(March 2023)
Full text access
P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS
Visits
230
Wai Kay Seto1, Ting-Tsung Chang2, Abhijit Chowdhry3, Chi-Yi Chen4, Mustafa Kemal Celen5, Xiaoli Ma6, Mang Ma7, Ajay Duseja8, Ki Tae Yoon9, Wan Cheng Chow10, Leland Yee11, Gregor Weber11, Ms Jin Youn11, John F. Flaherty11, Anuj Gaggar11, Bing Gao11, Gregory Camus11, Eric Bassetti11, Jae Seok Hwang12, Tetshuro Inokuma13..., Young- Suk Lin14, Edward J. Gane15Ver más
1 The University of Hong Kong, Hong Kong, Hong Kong
2 National Cheng-Kung University Hospital, Tainan, Taiwan
3 Institute of Post Graduate Medical Education and Research, Kolkata, India
4 Chia-Yi Christian Hospital, Chia-Yi, Taiwan
5 Dicle U¨Niversitesi Hastanesi Enfeksiyon Hastaliklari Anabilim Dali, Diyarbakir, Turkey
6 Xiaoli Ma, P.C., Philadelphia, USA
7 Zeidler Ledcor Centre, Edmonton, Canada
8 Postgraduate Institute of Medical Education & Research, Chandigarh, India
9 Pusan National University Yangsan Hospital, Yangsan, Korea
10 Singapore General Hospital, Singapore, Singapore
11 Gilead Sciences Inc., Foster City, USA
12 Keimyung University Dongsan Medical Center, Daegu, Korea
13 Kobe City Medical Center General Hospital, Kobe, Japan
14 Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
15 Liver Unit University of Auckland, Grafton, New Zealand
Ver más
This item has received
Article information
Special issue
This article is part of special issue:
Vol. 28. Issue S1

Abstracts of the 2022 Annual Meeting of the ALEH

More info
Introduction and Objectives

Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-blind (DB), randomized (2:1), Phase 3 studies (HBeAg-negative patients [N = 425] and HBeAg-positive patients [N = 873]), TAF demonstrated antiviral efficacy non-inferior to that of TDF with superior renal and bone safety. After completing three years of DB treatment, all patients were eligible to receive open-label (OL) TAF through Year eight. Here we present study results for Year five.

Materials and Methods

Efficacy was assessed by serial virologic, biochemical, and serologic assessments, while safety data included changes in renal function and changes in hip and spine bone mineral density. Resistance testing and phenotyping were performed annually through Year 5.

Results

Of 1298 randomized and treated patients, 1157 (89%; 775 TAF; 382 TDF) entered OL, at year 5, 999 (77%; 675 TAF, 136 TDFTAF OL 3y, 188 TDF-TAF OL 2y) patients remained on treatment. High rates of virologic control were achieved and maintained in patients receiving TAF throughout and for TDF patients who switched to TAF at Weeks 96 or 144. Rates of ALT normalization and serologic responses were also comparable among groups. Eight patients are undergoing phenotypic testing to assess resistance. Adverse events (AEs) leading to discontinuation were low and similar among groups. Renal and bone outcomes were improved following the switch to OL TAF from TDF.

Conclusions

After five years of treatment, virologic suppression rates remained high, and TAF was safe and well tolerated, with improved renal and bone safety in patients switching from TDF.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos